VASP and prostate neoplasm: Another study suggests that EGF receptor‐mediated prostate tumour progression is dependent on STAT3, which regulates the expression of VASP (motility‐limiting vasodilator‐stimulated phosphoprotein), and the apoptosis nexus CASP3.